Entrada Therapeutics (TRDA) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing EEV™-therapeutics for efficient intracellular delivery of RNA- and protein-based medicines targeting neuromuscular and ocular diseases.

• Lead programs focus on Duchenne muscular dystrophy (exon 44, 45, 50, 51 skipping); two candidates in clinical development, with additional regulatory filings planned through 2026.

• Strategic partnership with Vertex Pharmaceuticals for a clinical-stage program in myotonic dystrophy type 1.

• Cash, cash equivalents, and marketable securities of $326.8 million as of September 30, 2025, expected to fund operations into Q3 2027.

Financial performance and metrics

• $326.8 million in cash, cash equivalents, and marketable securities as of September 30, 2025.

• Sufficient liquidity to fund operations into the third quarter of 2027 based on current operating plans.

Use of proceeds and capital allocation

• Net proceeds from securities sales intended for general corporate purposes, including R&D, clinical development, working capital, and capital expenditures.

• Management retains broad discretion over allocation; proceeds may be temporarily invested in short-term, investment-grade instruments.